Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirabrutinib in healthy volunteers and rheumatoid arthritis
NCT02626026Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tirabrutinib in rheumatoid arthritis (RA) (6 arms), sponsored by Gilead Sciences. Primary endpoints: Treatment-Emergent Adverse Events, Treatment-Emergent Laboratory Abnormalities and 7 more. Started Jan 2016; status: completed.
02
Drugs
tirabrutinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02626026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626026.